Get the Stockscreener App
31.82
2.48%
0.77
Avidity Biosciences Inc stock is traded at $31.82, with a volume of 2.57M.
It is up +2.48% in the last 24 hours and down -27.10% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$31.05
Open:
$30.92
24h Volume:
2.57M
Relative Volume:
2.09
Market Cap:
$3.80B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.26
EPS:
-3.1
Net Cash Flow:
$-188.51M
1W Performance:
-2.06%
1M Performance:
-27.10%
6M Performance:
-15.39%
1Y Performance:
+278.81%
1-Day Range:
$30.85
$32.63
1-Week Range:
$30.07
$34.35
52-Week Range:
$8.49
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
31.82 | 3.80B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences CFO sells $364,191 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CHRO Teresa McCarthy sells $364,191 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Grants Major Stock Awards Package to Expand Team with 37 New Hires - StockTitan
Avidity Biosciences (NASDAQ:RNA) Shares Up 3.2%Time to Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at HC Wainwright - MarketBeat
Avidity Biosciences shares initiated with Buy on establishment By Investing.com - Investing.com UK
What 8 Analyst Ratings Have To Say About Avidity Biosciences - Benzinga
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $1,040,384.30 in Stock - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 11,151 Shares - MarketBeat
Avidity Biosciences' CSTO Flanagan sells $416,153 in stock - Investing.com
Avidity Biosciences' CSTO Flanagan sells $416,153 in stock By Investing.com - Investing.com UK
Avidity Biosciences CEO Sarah Boyce sells $1.04 million in stock - Investing.com
Avidity Biosciences CEO Sarah Boyce sells $1.04 million in stock By Investing.com - Investing.com UK
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $831,605 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences CHRO Teresa McCarthy sells $831,605 in stock - Investing.com India
Geode Capital Management LLC Has $118.77 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Gap DownHere's What Happened - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Barclays PLC - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Lord Abbett & CO. LLC - MarketBeat
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $858,480.00 in Stock - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Avidity Biosciences' CSTO Flanagan sells $858,400 in stock By Investing.com - Investing.com UK
Avidity Biosciences Becomes Oversold (RNA) - Nasdaq
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
Avidity Biosciences to Participate in Upcoming Investor Conference - The Eastern Progress Online
State Street Corp Grows Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Neo Ivy Capital Management Acquires Shares of 16,596 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - Victoria Advocate
Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases - Seeking Alpha
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - The Eastern Progress Online
Wellington Management Group LLP Acquires 3,228,923 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Castleark Management LLC Buys New Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Buy" by Analysts - MarketBeat
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) - The Eastern Progress Online
Avidity Biosciences Announces Proposed Public Offering of Common Stock - The Eastern Progress Online
Trend Tracker for (RNA) - Stock Traders Daily
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by RA Capital Management L.P. - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by RTW Investments LP - MarketBeat
Janus Henderson Group PLC Raises Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Cinctive Capital Management LP Sells 35,808 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Manufacturers Life Insurance Company Lowers Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Alethea Capital Management LLC - MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MacLean Michael F | Chief Financial Officer |
Dec 18 '24 |
Sale |
32.66 |
11,151 |
364,192 |
82,942 |
| Boyce Sarah | President and CEO |
Dec 18 '24 |
Sale |
32.66 |
31,855 |
1,040,384 |
265,308 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 18 '24 |
Sale |
32.66 |
11,151 |
364,192 |
82,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 16 '24 |
Option Exercise |
14.22 |
25,000 |
355,500 |
119,018 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 16 '24 |
Sale |
33.26 |
25,000 |
831,605 |
94,018 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):